HMOX1 and depressive symptom measurement: Consistent with these data, the current study characterized meloxicam’s antioxidant effects by diminishing 8-OHdG, downregulating the pro-oxidants NOX1 and NOX4, and activating the antioxidant/cytoprotective Nrf2/HO-1 pathway in the hippocampi of rats with CRS-evoked depression, resulting in improved depressive behavioral outcomes, including attenuated anhedonia and despair.